• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

相似文献

1
Donor CYP3A5 genotype influences tacrolimus disposition on the first day after paediatric liver transplantation.供体CYP3A5基因分型影响小儿肝移植术后第一天他克莫司的处置。
Br J Clin Pharmacol. 2017 Jun;83(6):1252-1262. doi: 10.1111/bcp.13219. Epub 2017 Jan 31.
2
Impact of donor genotype on pharmacokinetics of tacrolimus in South African paediatric liver transplant patients.供体基因型对南非儿科肝移植患者他克莫司药代动力学的影响。
S Afr Med J. 2024 Apr 24;114(3b):e1367. doi: 10.7196/SAMJ.2024.v114i3b.1367.
3
Influence of donor liver CYP3A4*20 loss-of-function genotype on tacrolimus pharmacokinetics in transplanted patients.供体肝脏CYP3A4*20功能缺失基因型对移植患者他克莫司药代动力学的影响。
Pharmacogenet Genomics. 2018 Feb;28(2):41-48. doi: 10.1097/FPC.0000000000000321.
4
Early impact of donor CYP3A5 genotype and Graft-to-Recipient Weight Ratio on tacrolimus pharmacokinetics in pediatric liver transplant patients.儿童肝移植患者中供体 CYP3A5 基因型和移植物与受者体重比对他克莫司药代动力学的早期影响。
Sci Rep. 2021 Jan 11;11(1):443. doi: 10.1038/s41598-020-79574-7.
5
Beneficial effects of Wuzhi Capsule on tacrolimus blood concentrations in liver transplant patients with different donor-recipient CYP3A5 genotypes.五指胶囊对不同供受者 CYP3A5 基因型肝移植患者他克莫司血药浓度的有益影响。
J Clin Pharm Ther. 2022 Feb;47(2):200-210. doi: 10.1111/jcpt.13533. Epub 2021 Oct 28.
6
Effects of combinational CYP3A5 6986A>G polymorphism in graft liver and native intestine on the pharmacokinetics of tacrolimus in liver transplant patients: a meta-analysis.移植肝和自身肠道中CYP3A5 6986A>G基因多态性组合对肝移植患者他克莫司药代动力学的影响:一项荟萃分析
Ther Drug Monit. 2014 Aug;36(4):442-7. doi: 10.1097/FTD.0000000000000032.
7
Influence of cytochrome P450 (CYP) 3A4*1G polymorphism on the pharmacokinetics of tacrolimus, probability of acute cellular rejection, and mRNA expression level of CYP3A5 rather than CYP3A4 in living-donor liver transplant patients.细胞色素 P450(CYP)3A4*1G 多态性对活体肝移植患者他克莫司药代动力学、急性细胞排斥反应概率和 CYP3A5(而非 CYP3A4)mRNA 表达水平的影响。
Biol Pharm Bull. 2013;36(11):1814-21. doi: 10.1248/bpb.b13-00509.
8
CYP3A7, CYP3A4, and CYP3A5 genetic polymorphisms in recipients rather than donors influence tacrolimus concentrations in the early stages after liver transplantation.受者而非供者的 CYP3A7、CYP3A4 和 CYP3A5 基因多态性影响肝移植后早期他克莫司的浓度。
Gene. 2022 Jan 30;809:146007. doi: 10.1016/j.gene.2021.146007. Epub 2021 Oct 22.
9
CYP3A pharmacogenetics and tacrolimus disposition in adult heart transplant recipients.CYP3A药物遗传学与成人心脏移植受者中环孢素A的处置
Clin Transplant. 2016 Sep;30(9):1074-81. doi: 10.1111/ctr.12790. Epub 2016 Jul 11.
10
Impact of cytochrome P450 3A5 polymorphism in graft livers on the frequency of acute cellular rejection in living-donor liver transplantation.细胞色素 P450 3A5 多态性对活体肝移植供体肝脏中急性细胞排斥反应频率的影响。
Pharmacogenet Genomics. 2014 Jul;24(7):356-66. doi: 10.1097/FPC.0000000000000060.

引用本文的文献

1
Machine-learning model to predict the tacrolimus concentration and suggest optimal dose in liver transplantation recipients: a multicenter retrospective cohort study.机器学习模型预测肝移植受者他克莫司浓度并建议最佳剂量:一项多中心回顾性队列研究。
Sci Rep. 2024 Aug 28;14(1):19996. doi: 10.1038/s41598-024-71032-y.
2
Development of a predictive nomogram for switching immunosuppressive drugs in pediatric liver transplant recipients.儿童肝移植受者免疫抑制药物转换预测列线图的开发
Front Pediatr. 2023 Oct 19;11:1226816. doi: 10.3389/fped.2023.1226816. eCollection 2023.
3
Genotype-guided model significantly improves accuracy of tacrolimus initial dosing after liver transplantation.基因型指导模型显著提高肝移植后他克莫司初始给药的准确性。
EClinicalMedicine. 2022 Nov 24;55:101752. doi: 10.1016/j.eclinm.2022.101752. eCollection 2023 Jan.
4
Pharmacogene Variants Associated with Liver Transplant in a Twelve-Year Clinical Follow-Up.一项为期12年临床随访中与肝移植相关的药物基因变异
Pharmaceutics. 2022 Feb 3;14(2):354. doi: 10.3390/pharmaceutics14020354.
5
Monitoring Tacrolimus Concentrations in Whole Blood and Peripheral Blood Mononuclear Cells: Inter- and Intra-Patient Variability in a Cohort of Pediatric Patients.监测全血和外周血单个核细胞中的他克莫司浓度:一组儿科患者的患者间和患者内变异性
Front Pharmacol. 2021 Nov 5;12:750433. doi: 10.3389/fphar.2021.750433. eCollection 2021.
6
Genotyping in Clinical Practice: Ready for Implementation?临床实践中的基因分型:准备好实施了吗?
Front Genet. 2021 Jul 8;12:711943. doi: 10.3389/fgene.2021.711943. eCollection 2021.
7
Early impact of donor CYP3A5 genotype and Graft-to-Recipient Weight Ratio on tacrolimus pharmacokinetics in pediatric liver transplant patients.儿童肝移植患者中供体 CYP3A5 基因型和移植物与受者体重比对他克莫司药代动力学的早期影响。
Sci Rep. 2021 Jan 11;11(1):443. doi: 10.1038/s41598-020-79574-7.
8
Tacrolimus and Sirolimus Once Daily Monotherapy Regimen as a Safe and Effective Long-Term Maintenance Immunosuppressive Therapy in Pediatric Liver Transplantation.他克莫司和西罗莫司每日一次单药治疗方案作为小儿肝移植安全有效的长期维持免疫抑制疗法
Int J Organ Transplant Med. 2020;11(4):177-184.
9
Microfluidics as a Novel Tool for Biological and Toxicological Assays in Drug Discovery Processes: Focus on Microchip Electrophoresis.微流控技术作为药物发现过程中生物和毒理学分析的新型工具:聚焦微芯片电泳
Micromachines (Basel). 2020 Jun 15;11(6):593. doi: 10.3390/mi11060593.

本文引用的文献

1
The Concise Guide to PHARMACOLOGY 2015/16: Enzymes.《2015/16药理学简明指南:酶》
Br J Pharmacol. 2015 Dec;172(24):6024-109. doi: 10.1111/bph.13354.
2
The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands.《2016年IUPHAR/BPS药理学指南:迈向1300个蛋白质靶点与6000种配体之间的精准定量相互作用》
Nucleic Acids Res. 2016 Jan 4;44(D1):D1054-68. doi: 10.1093/nar/gkv1037. Epub 2015 Oct 12.
3
Personalizing initial calcineurin inhibitor dosing by adjusting to donor CYP3A-status in liver transplant patients.通过根据肝移植患者供体的细胞色素P450 3A(CYP3A)状态调整剂量来实现钙调神经磷酸酶抑制剂初始给药的个体化。
Br J Clin Pharmacol. 2015 Dec;80(6):1429-37. doi: 10.1111/bcp.12747. Epub 2015 Oct 26.
4
Choosing the right dose of tacrolimus.选择合适的他克莫司剂量。
Arch Dis Child. 2015 Apr;100(4):406-13. doi: 10.1136/archdischild-2013-305888. Epub 2014 Nov 21.
5
Influence of donor-recipient CYP3A4/5 genotypes, age and fluconazole on tacrolimus pharmacokinetics in pediatric liver transplantation: a population approach.供体-受体CYP3A4/5基因分型、年龄及氟康唑对小儿肝移植中环孢素A药代动力学的影响:群体分析方法
Pharmacogenomics. 2014 Jun;15(9):1207-21. doi: 10.2217/pgs.14.75.
6
Addressing phenoconversion: the Achilles' heel of personalized medicine.应对表型转换:个性化医疗的致命弱点。
Br J Clin Pharmacol. 2015 Feb;79(2):222-40. doi: 10.1111/bcp.12441.
7
Pharmacogenetic considerations for optimizing tacrolimus dosing in liver and kidney transplant patients.肝、肾移植患者中环孢素剂量优化的药物遗传学考虑因素。
World J Gastroenterol. 2013 Dec 28;19(48):9156-73. doi: 10.3748/wjg.v19.i48.9156.
8
The role of pharmacogenetics in the disposition of and response to tacrolimus in solid organ transplantation.药物遗传学在实体器官移植中他克莫司的处置及反应中的作用。
Clin Pharmacokinet. 2014 Feb;53(2):123-39. doi: 10.1007/s40262-013-0120-3.
9
Developmental changes in the expression and function of cytochrome P450 3A isoforms: evidence from in vitro and in vivo investigations.细胞色素 P450 3A 同工型表达和功能的发育变化:来自体外和体内研究的证据。
Clin Pharmacokinet. 2013 May;52(5):333-45. doi: 10.1007/s40262-013-0041-1.
10
Inherent sex-dependent regulation of human hepatic CYP3A5.人类肝 CYP3A5 的固有性别依赖性调节。
Br J Pharmacol. 2013 Feb;168(4):988-1000. doi: 10.1111/j.1476-5381.2012.02222.x.

供体CYP3A5基因分型影响小儿肝移植术后第一天他克莫司的处置。

Donor CYP3A5 genotype influences tacrolimus disposition on the first day after paediatric liver transplantation.

作者信息

Calvo Pier Luigi, Serpe Loredana, Brunati Andrea, Nonnato Antonello, Bongioanni Daniela, Olio Dominic Dell', Pinon Michele, Ferretti Carlo, Tandoi Francesco, Carbonaro Giulia, Salizzoni Mauro, Amoroso Antonio, Romagnoli Renato, Canaparo Roberto

机构信息

Department of Pediatrics and Public Health Sciences, Division of Pediatric Gastroenterology, A.O.U. Città della Salute e della Scienza of Torino, University of Torino, Torino, Italy.

Department of Drug Science and Technology, University of Torino, Torino, Italy.

出版信息

Br J Clin Pharmacol. 2017 Jun;83(6):1252-1262. doi: 10.1111/bcp.13219. Epub 2017 Jan 31.

DOI:10.1111/bcp.13219
PMID:28044353
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5427244/
Abstract

AIM

The aim of the present study was to investigate the influence of the cytochrome P450 (CYP) 3A4/5 genotype in paediatric liver transplant recipients and donors, and the contribution of age and gender to tacrolimus disposition on the first day after transplantation.

METHODS

The contribution of the CYP3A4/5 genotype in paediatric liver transplant recipients and donors to the tacrolimus blood trough concentrations (C ) and the tacrolimus concentration/weight-adjusted dose ratio on day 1 was evaluated in 67 liver-transplanted children: 33 boys and 34 girls, mean age 4.5 years.

RESULTS

Donor CYP3A5 genotype appears to be significantly associated with tacrolimus disposition on the first day after liver transplantation (P < 0.0002). Other physiological factors, such as recipient age and donor gender may also play a role and lead to significant differences in tacrolimus C and tacrolimus concentration/weight-adjusted dose ratio on day 1. However, according to the general linear model, only recipient age appears to be independently associated with tacrolimus disposition on the first day after liver transplantation (P < 0.03). Indeed, there was a faster tacrolimus metabolism in children under 6 years of age (P < 0.02).

CONCLUSIONS

Donor CYP3A5 genotype, recipient age and, to a lesser extent, donor gender appear to be associated with tacrolimus disposition on day 1 after transplant. This suggests that increasing the starting tacrolimus doses in paediatric patients under 6 years of age who receive a graft from a male extensive metabolizer may enhance the possibility of their tacrolimus levels reaching the therapeutic range sooner.

摘要

目的

本研究旨在调查细胞色素P450(CYP)3A4/5基因型在小儿肝移植受者和供者中的影响,以及年龄和性别对移植后第一天他克莫司处置的作用。

方法

在67例肝移植儿童中评估了小儿肝移植受者和供者的CYP3A4/5基因型对他克莫司血谷浓度(C)和移植后第1天他克莫司浓度/体重调整剂量比的作用:33例男孩和34例女孩,平均年龄4.5岁。

结果

供者CYP3A5基因型似乎与肝移植后第一天他克莫司的处置显著相关(P<0.0002)。其他生理因素,如受者年龄和供者性别也可能起作用,并导致移植后第1天他克莫司C和他克莫司浓度/体重调整剂量比出现显著差异。然而,根据一般线性模型,只有受者年龄似乎与肝移植后第一天他克莫司的处置独立相关(P<0.03)。事实上,6岁以下儿童的他克莫司代谢更快(P<0.02)。

结论

供者CYP3A5基因型、受者年龄以及在较小程度上供者性别似乎与移植后第1天他克莫司的处置相关。这表明,对于接受来自男性广泛代谢者移植物的6岁以下小儿患者,增加他克莫司起始剂量可能会提高其他克莫司水平更快达到治疗范围的可能性。